FDA Grants IDE Approval for OCS Heart ENHANCE Trial
Andover, Massachusetts | February 9, 2026 — TransMedics Group has received full and unconditional Investigational Device Exemption (IDE) approval...
ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody NSCLC Oncology oncology innovation oncology research Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
Andover, Massachusetts | February 9, 2026 — TransMedics Group has received full and unconditional Investigational Device Exemption (IDE) approval...
SOUTH SAN FRANCISCO, Calif., Nov. 24, 2025 — CareDx, Inc., a leader in precision medicine for transplant patients, announced...
